OIPE
OCT 25 2007
PATENT & TRADEMARK OFFICE

Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 8

Complete if Known	
Application Number	10/759841
Filing Date	01/15/2004
First Named Inventor	Michael Graham
Art Unit	1635
Examiner Name	B. Whiteman
Attorney Docket Number	025122.0101N3US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		20020150986	10/17/2002	L.F. Lau	
		4,689,320	08/25/1987	A. Kaji	
		5,107,065	04/21/1992	Shewmaker et al.	
		5,514,546	05/07/1996	E. Kool	
		5,631,148	05/20/1997	M. Urdea	
		5,747,308	05/05/1998	Bebbington et al.	
		5,858,981	01/21/1999	Schreiber et al.	
		5,891,855	04/06/1999	R. Florkiewicz	
		2005/0250208	11/10/2005	Graham et al.	
		2002/0168707	11-14-2002	M. W. Graham	
		2003/0061626	03-27-2003	Plaetinck et al.	
		2004/0022748	02-05-2004	Ananthapadmanabhan et al.	
		2004/0138168	07-15-2004	Satishchandran et al.	
		2006/0014715	01-19-2006	Graham et al.	
		2006/0178335	08/10/2006	Waterhouse et al.	
		2004/0214330	10/28/2004	Waterhouse et al.	
		3,931,397	01-06-1976	Harnden	
		4,130,641	12-19-1978	Ts'o et al.	
		4,283,393	08-11-1981	Field et al.	
		4,469,863	09-04-1984	Ts'o et al.	
		4,605,394	08-12-1986	Skurkovich	
		5,024,938	06-18-1991	Nozaki et al.	
		5,173,410	12-22-1992	Ahlquist	
		5,365,015	11-15-1994	Grierson et al.	
		5,453,566	09-26-1995	Shewmaker et al.	
		5,624,803	04-29-1997	Noonberg et al.	
		5,643,762	07-01-1997	Ohshima et al.	
		5,683,985	11-04-1997	Chu et al.	
		5,691,140	11-25-1997	Noren et al.	
		5,693,773	12-02-1997	Kandimalla et al.	
		5,739,309	04-14-1998	Dattagupta et al.	
		5,747,338	05-05-1998	Giese et al.	
		5,795,715	08-18-1998	Livache et al.	
		5,808,036	09-15-1998	Kool	
		5,850,026	12-15-1998	DeBonte et al.	
		5,874,555	02-23-1999	Dervan et al.	
		5,908,779	06-01-1999	Carmichael et al.	
		5,972,704	10-26-1999	Draper et al.	

Examiner Signature		Date Considered	

Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/759841
				Filing Date	01/15/2004
				First Named Inventor	Michael Graham
(Use as many sheets as necessary)				Art Unit	1635
				Examiner Name	B. Whiteman
Sheet	2	of	8	Attorney Docket Number	025122.0101N3US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		6,010,908	01-04-2000	Gruenert et al.	
		6,022,863	02-08-2000	Peyman	
		6,133,024	10-17-2000	Helene et al.	
		6,291,504	09-18-2001	Nugiel et al.	
		6,369,038	04-09-2002	Blumenfeld et al.	
		6,372,965	04-16-2002	Lightner et al.	
		6,531,647	03-11-2003	Baulcombe et al.	
		6,635,805	10-21-2003	Baulcombe et al.	
		6,610,321	08-26-03	Huang et al.	
		2007/0078105	04/05/2007	Waterhouse et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
		WO 97 11170	03/27/1997	P.A. Zamecnik		
		WO 97 44460	11/27/1997	Sanicola-Nadel et al.		
		EP-0213921-A2	03-11-1987	Hem Research, Inc.		
		EP-0281380-A2	09-07-1988	Hem Research, Inc.		
		EP-0286224-A2	10-12-1988	Hem Research, Inc.		
		EP-0300680-A2	01-25-1989	Hem Research, Inc.		
		EP-0303516-A2	02-15-1989	Hem Research, Inc.		
		EP-0306347-A2	03-08-1989	Hem Research, Inc.		
		EP-0308066-A2	03-22-1989	Hem Research, Inc.		
		EP-0318281-A2	05-31-1989	Hem Research, Inc.		
		EP-0325018-A2	07-26-1989	Hem Research, Inc.		
		EP-0347501-A1	12-27-1989	Hem Research, Inc.		
		EP-0350151-A2	01-10-1990	Hem Research, Inc.		
		EP-0983370-B1	03-08-2000	Sygenta Limited		
		AU-200195225-A1	01-31-2002	Benitic Australia Ltd.		
		CA-2012312	09-16-1990	Boehringer Ingelheim International GMBH		
		GB-2353282A-A	02-21-2001	Benitec Australia Ltd.		
		CA-2370628-A1	10-26-2000	American Home Products Corporation		
		GB-2377221-A	09-27-2001	Benitec Australia Ltd		
		WO-90/12094-A1	10-18-1990	The United States of America as represented by the Secretary, U.S. Department of Commerce		

Examiner Signature		Date Considered	

Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/759841
				Filing Date	01/15/2004
				First Named Inventor	Michael Graham
				Art Unit	1635
(Use as many sheets as necessary)				Examiner Name	B. Whiteman
Sheet	3	of	8	Attorney Docket Number	025122.0101N3US

		WO-90/14090-A1	11-29-1990	Hem Research, Inc.		
		WO-92/18522-A1	10-29-1992	The Salk Institute for Biological Studies		
		WO-95/03406-A2	02-02-1995	Gen-Probe Inc.		
		WO-95/18223-A1	07-06-1995	Centre National De La Recherche Scientifique		
		WO-95/18854-A1	07-13-1995	Gene Shears Pty., Ltd.		
		WO-95/34668-A2	12-21-1995	Biosource Technologies, Inc.		
		WO-95/35706-A1	11-14-1996	Hybridon, Inc.		
		WO-97/10360-A1	03-20-1997	Chiron Corporation		
		WO-97/11170-A1	03-27-1997	Worcester Foundation For Biomedical Research		
		WO-98/05770-A2	02-12-1998	Anmelder		
		JP-H09-110894-A	04-28-1997	Soyaku Gijutsu Kenkyusho:KK		
		JP-H09-227413-A	09-02-1997	Kirin Brewery Co. Ltd.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		Benitec Australia, Ltd. V. Nucleonics, Inc., U.S. Court of Appeals for the Federal Circuit, 06-1122, Judgment issued July 20, 2007.	
		Appeal No. T1491/05-3308, issued April 24, 2007, Technical Board of Appeal of the European Patent Office.	
		ABDURASHITOV et al., "BstAPI, an ApaBi Isoschizomer, Cleaves DNA at 5'GCANNNNNTGC-3'," Nucleic Acids Research, 1997, Vol. 25, No. 12, pp. 2301-2301.	
		BARABINO et al., "Inactivation of the Zebrafish Homologue of Chx10 by Antisense Oligonucleotides Causes Eye Malformations Similar to the Ocular Retardation Phenotype," Mech. Dev. 1997 Vo. 63, pp. 133-143	
		BUCHMAN et al., "Comparison of Intron-Dependent and Intron-Independent Gene Expression," Mol. Cel. Biol. 1988, Vol. 8, No. 10, pp. 4395-4405.	
		DAY et al., "Expression of an Antisense Viral Gene in Transgenic Tobacco Confers Resistance to the DNA Virus Tomato Golden Mosaic Virus" Proc Nat. Aca. Sci., 1995, Vol. 88, pp. 6721-6725	
		DHALLA et al. "chk-YB-1b, a Y-box Binding Protein Activates Transcription from Rat Alpha1(I) Procollagen Gene Promoter,"Biochem J., 1998, Vol. 336, No. 2, pp. 373-379.	
		Exhibit A from Benitec Australia Ltd. v. Nucleonics. Inc.. Civil Litigation Action No. 04-174	

Examiner Signature		Date Considered	

Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/759841
				Filing Date	01/15/2004
				First Named Inventor	Michael Graham
				Art Unit	1635
(Use as many sheets as necessary)				Examiner Name	B. Whiteman
Sheet	4	of	8	Attorney Docket Number	025122.0101N3US

		(D. Del.) (JJF). filed March 22. 2004. 380 pages	
		Exhibit B from Benitec Australia Ltd. v. Nucleonics. Inc.. Civil Litigation Action No. 04-174 (D. Del.) (JJF). filed March 22. 2004. 20 pages	
		GITLIN et al. "Poliovirus Escape from RNA Interference: Short Interfering RNA-Target Recognition and Implications for Therapeutic Approaches" Journal of Virology, 2005, pp. 1027-1035.	
		HASELBECK et al., "Minimum Intron Requirements for tRNA Splicing and Nuclear Transport in *Xenopus* Oocytes," Biochem, 1993, Vol. 32, No. 33, pp. 8575-8581.	
		LEVIN, et al., "Methods of Double-Stranded RNA-mediated Gene Inactivation in *Arabidopsis* and Their Use to Define an Essential Gene in Methionine Biosynthesis," Plant Molecular Biology, 2000, Vol. 44, pp. 759-775.	
		McGARRY et al., "Inhibition of Heat Shock Protein Synthesis by Heat-Inducible Antisense RNA," Proc. Nat. Acad. Sci., 1986 Vol. 83, pp. 399-403	
		PARK et al., "Specific inhibition of HIV-1 gene expression of double-stranded RNA" Nucleic Acids Research Supplement No. 1: 219-220 (2001)	
		PARK et al. "Prevention of HIV-1 Infection in Human Peripheral Blood Mononuclear Cells by Specific RNA Interference," Nucleic Acids Research, 2002, Vol. 30, No. 22, pp. 4830-4835.	
		POWELL-COFFMAN et al.. "Onset of C. Elegans Gastrulation is Blocked by Inhibition of Embryonic Transcription with an RNA Polymerase Antisense RNA," Dev. Biol., 1996, Vol. 178, pp. 472-483,	
		ROBBINS et al., "Sensing the Danger in RNA" Nature Medicine, 2005, Vol. 1, No. 3, pp. 250-251.	
		STAM et al,. "Post-Transcriptional Silencing of Chalcone Synthase in Petunia by Inverted Transgene Repeats," The Plant Journal, 1997, Vol. 12, No. 1, pp. 63-82.	
		SWAMYNATHAN et al., "Chicken YB-2, a Y-Box Protein, is a Potent Activator of Rous Sarcoma Virus Long Terminal Repeat-Driven Transcription in Avian Fibroblasts," Journal of Virology, 1997, Vol. 71, No. 4, pp. 2873-2880.	
		TANG, et al., "Self-Stabilized Antisense Oligodeoxynucleotide Phosphorothioates: Properties and Anti-HIV Cavity," Nucleic Acids Research, 1993, Vol. 21, No. 11, pp. 2729-2735.	
		YAMAMOTO et al., "Double-stranded *nef* RNA Interferences with Human Immunodeficiency Virus Type 1 Replication," Microbiol. Immunol., 2002, Vol. 46, No. 100, pp. 809-817.	
		ZHANG et al., "Single Processing Center Models for Human Dicer and Bacterial NRase III," Cell, 2004, Vol. 118, pp. 57-68.	
		ZHAO, et al.,"Generating Loss-of-Function Phenotype of the Fushi Tarazu Gene with a Targeted Ribozyme in Drosophila," Nature, 1993, Vol. 365, pp. 448-451.	
		AGRAWAL (1996) Trends Biochem. Sci. 14: 376.	
		AKGÜN (September 1997) Mol. Cell. Biol. 17: 5559.	
		AKHTAR (1996) J. Antimicrob. Chemother. 38: 159.	
		BAHNER (1996) J. Virol. 70: 4352.	
		BARBEAU (1996) Biochim. Biophys. Acta 1307: 220.	
		BAUM (1983) Biochem. Biophys. Res. Commun. 114: 41.	
		BIGLER (1995) EMBO J. 14: 5710.	

Examiner Signature		Date Considered	

Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/759841
				Filing Date	01/15/2004
				First Named Inventor	Michael Graham
				Art Unit	1635
(Use as many sheets as necessary)				Examiner Name	B. Whiteman
Sheet	5	of	8	Attorney Docket Number	025122.0101N3US

		BISAT (1988) Nucl. Acids Res. 13: 6067.	
		BRANCH (February 1998) Trends Biochem. Sci. 23: 45.	
		BROWN (January 1993) J. Biol. Chem. 268: 713.	
		BRUMMELKAMP et al. (April 2002) Science 296: 550-553.	
		BUCHAN (1994) Br. J. Pharmacol. 112: 1251.	
		CAPLEN ET AL. (2000) "dsRNA - mediated gene silencing in cultured *Drosphila* cells: a tissue culture model for the analysis of RNA interference" Gene 252: 95-105.	
		CHERNAJOVSKY (1996) DNA Cell Biol. 15: 965.	
		CHRISTY (1988) Mol. Cell. Biol. 8: 1093.	
		CLUSEL (1993) Nucl. Acids Res. 21: 3405.	
		CLUSEL (1995) Gene Expression 4: 301.	
		COLEMAN et al. (1984) "The use of RNAs complementary to specific mRNAs to regulate the expression of individual bacterial genes" Cell 37: 429-36	
		DECOY (1995) J. Clin. Invest. 95: 2749.	
		DOBRIKOVA (1996) FEBS Lett. 382: 327.	
		DOLNICK (1997) Pharm. Ther. 75: 179.	
		DOUGHERTY (1995) Curr. Opin. Cell Biol. 7: 399.	
		DRONKERT (2000) Mol. Cell. Biol. 20: 3147.	
		ELROY-STEIN (1990) Proc. Nat'l Acad. Sci. USA 87: 6743.	
		ESCUDÉ (April 1996) Proc. Nat'l Acad. Sci. USA 93: 4365.	
		FARUQI (October 1997) J. Immunol. 159: 3989.	
		FIASCHI (November 1997) FEBS Lett. 417: 130.	
		FINKLER (1992) Mol. Genet. Genomics 233: 395.	
		FUERST (1986) Proc. Nat'l Acad. Sci. USA 83: 8122.	
		GAO (1997) Nucl. Acids Res. 25: 4740.	
		GESSANI (1989) J. Interferon Res. 9:543.	
		GIMMI (1989) Nucl. Acids Res. 17: 6983.	
		GIOVANNANGELI (Jan. 1997) Proc. Nat'l Acad. Sci. USA 94: 79.	
		GITLIN et al. (2005) Journal of Virology 79: 1027-1035.	
		GRAHAM, G. (1992) BioTech. 13: 780.	
		GRAHAM, G. et al. (1990) "RNA transcripts of the Human Immunodeficiency Virus Transactivation Response Element can inhibit action of the viral transactivator" Proc. Nat'l Acad. Sci. USA 87: 5817-21	
		GROGER (1989) Gene 81: 285.	
		HACKER (1995) Devel. 121: 1603.	
		HAINES (1991) J. Cell. Biochem. 46: 9.	
		HARBINDER (Nov. 1997) Proc. Nat'l Acad. Sci. USA 94: 13128.	
		HARCOURT (1998) Virol. 252: 179.	
		HARFE (1998) Genes Devel. 12: 2623.	
		HENDERSON (May 1993) Genetics 134: 57.	
		HIRASHIMA (1989) J. Biochem. 106: 163.	
		HIRASHIMA (Oct. 1986) Proc. Nat'l Acad. Sci. USA 83: 7726.	
		IMAZEKI (March 1988) J. Virol. 62: 861.	
		KENNERDELL et al. (July 2000) Nature Biotechnology 17: 896-898.	
		KIBLER ET AL. (1997) "Double-Stranded RNA is a Trigger for Apoptosis in Vaccinia Virus-	

Examiner Signature		Date Considered	

Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/759841
				Filing Date	01/15/2004
				First Named Inventor	Michael Graham
				Art Unit	1635
(Use as many sheets as necessary)				Examiner Name	B. Whiteman
Sheet	6	of	8	Attorney Docket Number	025122.0101N3US

		Infected Cells." Journal of Virology 71: 1992-2003.	
		KLAFF (1996) Plant Mol. Biol. 32: 89.	
		KRYSTAL (January 1990) Mol. Cell. Biol. 10: 4180.	
		LEE (1993) Cell 75: 843.	
		LEE (1996) Infect. Immun. 64: 4802.	
		MACÉ (1991) Res. Virol. 142: 213.	
		MATTHIEU (1992) Annals N.Y. Acad. Sci. 660: 188.	
		MAYNE (1988) Gene 66: 65.	
		MCCORMACK (1992) Virol. 188: 47.	
		MCNAIR (1994) J. Gen. Virol. 75: 1371.	
		MERCOLA (1995) Cancer Gene Ther. 2: 47.	
		METTE (2000) EMBO J. 19: 5194.	
		MIKOSHIBA (1990) Ann. N.Y. Acad. Sci. 605: 166.	
		MORISHITA (1996) Hypertension 27: 502.	
		MORRIS (August 2004) Science 305: 1289.	
		NAGY (February 1995) J. Biol. Chem. 270: 2755.	
		NOGUCHI (August 1994) J. Biol. Chem. 269: 29161.	
		PALMITER (1984) Cell 36: 869.	
		PE'ERY (1997) Methods 11: 371.	
		PEYMAN (January 1997) Basic Science of Vascular Disease (Chapter 17, p.17).	
		PRATT (1988) Nucl. Acids Res. 16: 3497.	
		RAPONI (May 2003) Nucl. Acids Res. 31: 4481.	
		RATCLIFF (June 1997) Science 276: 1558.	
		RESNEKOV (June 1989) J. Biol. Chem. 264: 9953.	
		REUBEN (1994) Biochim. Biophys. Acta 1219: 321.	
		ROBERTSON (1996) Nucl. Acids Res. 24: 1465.	
		ROCHELEAU (August 1997) Cell 90: 707.	
		RODRIGUEZ (October 1990) J. Virol. 64: 4851.	
		ROY (August 1990) Eur. J. Biochem. 191: 647.	
		RUSKIN (1993) Genetics 133: 43.	
		SABL (1996) Genetics 142: 447.	
		SCHMITT (1986) Differentiation 30: 205.	
		SEIFE ET AL. (2003) "Breakthrough of the Year" Science 302: 2038-45.	
		SHAFFER (2004) Biotech News 24: 30.	
		SHARP (1999) Gene Devel. 13: 139.	
		SILVERMAN (1992) J. Biol. Chem. 267: 9738.	
		SIMONS (1988) Gene 72: 35.	
		SMOLINSKI (1995) Blood 85: 2945.	
		SMYTHE (1995) Inflamm. Res. 44: 11.	
		SONODA (1996) Vaccine 14: 277.	
		SULLENGER (1990) Cell 63: 601.	
		SUN (October 1994) Proc. Nat'l Acad. Sci. USA 91: 9715.	
		SWEETSER (1988) Proc. Nat'l Acad. Sci. USA 85: 9611.	
		SYMINGTON (2002) Microbiol. Mol. Biol. Rev. 66: 630.	
		TABARA (1998) Science 282: 369.	

Examiner Signature		Date Considered	

Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/759841
				Filing Date	01/15/2004
				First Named Inventor	Michael Graham
				Art Unit	1635
(Use as many sheets as necessary)				Examiner Name	B. Whiteman
Sheet	7	of	8	Attorney Docket Number	025122.0101N3US

		TANAKA (1994) Nucl. Acids Res. 22: 3069.	
		TAVERNARAKIS et al. (February 2000) Nature Genetics 24: 180-183.	
		TIMMONS (November 1998) Nature 395: 854.	
		TOSIC (1990) EMBO J. 9: 401.	
		USDIN (1993) BioTech. 14: 222.	
		VAN STEEG (1991) Biochem. J. 274: 521.	
		VOLLOCH (1994) Nucl. Acids Res. 22: 5302.	
		WAGNER et al. (1998) "Double-stranded RNA poses puzzle" Nature 391: 744-45	
		WANG (1994) Biol. Reprod. 51: 1022.	
		WATERHOUSE (1999) Proc. Nat'l Acad. Sci. USA 95: 13959.	
		WILLIAMS (1986) Nature 322: 275.	
		WOLFFE (1997) Current Biol. 7: R796.	
		WU (1994) J. Interferon Res. 14: 357.	
		WU (1996) J. Biol. Chem. 271: 1756.	
		XIONG (1995) Endocrin. 136: 1828.	
		YARNEY (1993) Mol. Cell. Endroc. 93: 219.	
		YAMAMOTO et al. (2002) Microbiol. Immunol. 46: 809-817.	
		YU (1994) Gene Therap. 1: 13.	
		ZAKHARYAN (1986) Doklady Akadem: Nauk SSR 288: 1251.	
		ZHENHUA (1991) Chinese J. Biotech. 7: 279.	
		Decision to refuse a European patent application dated July 11, 2005, filed in EP 99 910 039.9.	
		Appeal against decision to refuse a European patent application issued July 11, 2005 in EP 99 910 039.9.	
		Minutes of Oral Proceeding dated July 12, 2005, filed in EP 99 910 039.9.	
		Reply to Summons to attend Oral Proceeding filed May 13, 2005 in European Patent Application No. 99 910 039.9-2401.	
		Request for correction of minutes filed August 2, 2005 in EP 99 910 039.9.	
		In re Opposition to Australian Patent Application No. 743316, Statement of Grounds and Particulars of Opposition.	
		In re Opposition to Australian Patent Application No. 743316, Statutory Declaration of Dr. Michael Wayne Graham.	
		In re Opposition to Australian Patent Application No. 743316, Declaration of Dr. Peter Waterhouse.	
		In re Opposition to Australian Patent Application No. 743316, Declaration of Dr. Robert De Feyter.	
		In re Opposition to Australian Patent Application No. 743316, Statutory Declaration of Ming-Bo Wang.	
		In re Opposition to Australian Patent Application No. 743316, Statutory Declaration of Dr. Robert Norman Rice.	
		In re Opposition to Australian Patent Application No. 743316, Statutory Declaration of Neil Andrew Smith.	
		In re Opposition to Australian Patent Application No. 743316, Statutory Declaration of Geoffrey Alan Ellacott.	
		In re Opposition to Australian Patent Application No. 743316, Statutory Declaration of Kenneth Clifford Reed.	

Examiner Signature		Date Considered	

Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/759841
				Filing Date	01/15/2004
				First Named Inventor	Michael Graham
				Art Unit	1635
(Use as many sheets as necessary)				Examiner Name	B. Whiteman
Sheet	8	of	8	Attorney Docket Number	025122.0101N3US

		In re Opposition to Australian Patent Application No. 743316, Statutory Declaration of William John Pickering.	
		Statement setting out the Grounds of Appeal dated November 11, 2005, filed in EP 99 910 039.9.	
		Table describing sequences used to inhibit viral replication. Annex A filed in EP 99 910 039.9.	
		Annex B filed in EP 99 910 039.9.	
		Annex C filed in EP 99 910 039.9	
		Annex D filed in EP 99 910 039.9	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	